<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675919</url>
  </required_header>
  <id_info>
    <org_study_id>TeLIPro</org_study_id>
    <nct_id>NCT03675919</nct_id>
  </id_info>
  <brief_title>TeLIPro Health Program - Active With Diabetes</brief_title>
  <acronym>TeLIPro</acronym>
  <official_title>The Telemedical Lifestyle Intervention Program TeLIPro (TeLIPro Health Program - Active With Diabetes)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Center of Diabetes and Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AOK Rhineland / Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Institute for Telemedicine and Health Promotion</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Center of Diabetes and Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized-controlled trial the hypothesis should be tested that the Telemedical
      Lifestyle Intervention Program TeLIPro could significantly improve HbA1c (primary outcome),
      body weight and composition, cardiovascular risk factors, quality of life, eating behavior,
      and medication demand (secondary outcomes) in type 2 diabetes mellitus (T2DM) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T2DM patients, assured at the health insurance AOK Rhineland / Hamburg will be randomized
      into two parallel groups. In addition to routine care both groups will be provided a scale as
      well as a step counter and access to a secured online portal. The TeLIPro group will
      additionally got a glucose meter with test stripes fpr self-monitoring of blood glucose and
      telemedical coaching.

      Participants of both groups will enter their anthropometric and metabolic data into a
      database on quarterly basis. In addition, the costs for diabetes-specific treatment,
      inpatient and outpatient treatment costs and drug costs will be analyzed on the basis of the
      routine data of the AOK Rhineland / Hamburg.

      Patient preference for type 2 diabetes intervention will be recorded using Discrete Choice
      Experiment (DCE) questionnaires at the beginning of the program and at the end of the
      intervention. As part of the development and validation of the DCE, focus groups are used to
      determine the DCE attributes. In addition, focus groups should also be used during the data
      collection in order to obtain additional information on patient preferences by means of
      qualitative analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of HbA1c change (in T2DM patients with diabetes duration of â‰¥ 5 years)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>remission rate</measure>
    <time_frame>12 months</time_frame>
    <description>number of participants with an HBA1c &lt;6.5% (in T2DM patients with diabetes duration of &lt; 5 years)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of fasting blood glucose change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of weight change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of body mass index change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of systolic blood pressure change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of diastolic blood pressure change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of total cholesterol change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-density lipoprotein (HDL) cholesterol change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of high-density lipoprotein (HDL) cholesterol change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low-density lipoprotein (LDL) cholesterol change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of low-density lipoprotein (LDL) cholesterol change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglyceride change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of triglyceride change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of steps</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of number of steps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antidiabetic medication change</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of antidiabetic medication change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diabetes-specific treatment costs</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of diabetes-specific treatment costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inpatient costs</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of inpatient costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>outpatient costs</measure>
    <time_frame>12 months</time_frame>
    <description>estimated treatment difference between groups of outpatient costs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2018</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will be provided a scale, a step counter as well as access to the online portal and will remain in routine care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TeLIPro group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The TeLIPro group will be provided a scale, a step counter, a blood glucose meter with test stripes as well as access to the online portal and will get telemedical coaching.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scale</intervention_name>
    <description>self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>TeLIPro group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Step counter</intervention_name>
    <description>self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>TeLIPro group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood glucose meter with test stripes</intervention_name>
    <description>self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal</description>
    <arm_group_label>TeLIPro group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Access to the online portal</intervention_name>
    <description>self-monitoring of health parameters</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>TeLIPro group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemedical coaching</intervention_name>
    <description>regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity</description>
    <arm_group_label>TeLIPro group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  body mass index of et least 27 kg/m2

        Exclusion Criteria:

          -  acute infections

          -  chronic diseases other than type 2 diabetes and hypertension (e.g., cancer, chronic
             obstructive pulmonary disease, asthma, dementia, chronic gut diseases, psychoses,
             liver cirrhosis, macronephropathy/nephropathy, kidney insufficiency with glomerular
             filtration rate &lt;30 ml/min/1.73 m2)

          -  acute chemotherapy or chronic cortisol treatment

          -  smoking cessation for &lt;3 months and/or planned smoking cessation during study

          -  pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Altpeter</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Institut fÃ¼r Telemedizin und GesundheitsfÃ¶rderung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sibel Altin</last_name>
    <role>Study Chair</role>
    <affiliation>AOK Rhineland / Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Icks, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Deusches Diabetes Zentrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Martin, MD</last_name>
    <phone>+49-(0)211-5660360</phone>
    <phone_ext>70</phone_ext>
    <email>stephan.martin@uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerstin Kempf, PhD</last_name>
    <phone>+49-(0)211-5660360</phone>
    <phone_ext>16</phone_ext>
    <email>kerstin.kempf@wdgz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West German Centre of Diabetes and Health</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <zip>40591</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Martin, MD</last_name>
      <phone>+49(0)211-5660360</phone>
      <phone_ext>70</phone_ext>
      <email>martin@wdgz.de</email>
    </contact>
    <contact_backup>
      <last_name>Kerstin Kempf, PhD</last_name>
      <phone>+49(0)211-5660360</phone>
      <phone_ext>16</phone_ext>
      <email>kerstin.kempf@wdgz.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West German Center of Diabetes and Health</investigator_affiliation>
    <investigator_full_name>Stephan Martin</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

